Aeterna Zentaris, Keryx deal

Aeterna and Keryx mutually terminated a deal that gave Keryx North American rights to Phase III cancer product perifosine ( KRX-0401). The move comes a month after perifosine missed the primary endpoint of median overall survival (OS) in the Phase III X-PECT trial to treat refractory metastatic colorectal cancer (mCRC) (see BioCentury, April 9). ...